Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients With Recurrent High Grade Glioma

NCT01156584 is registered in ClinicalTrials.gov with Tocagen Inc. as lead sponsor.

NCT NCT01156584
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01156584 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients With Recurrent High Grade Glioma
Lead sponsor
Tocagen Inc.
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2010
Completion date
August 18, 2016
Enrollment
54 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, glioblastoma